|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
And the Worst Biotech CEO of the Year is...
12/7/2012 7:33:50 AM
There is nothing like a drop in stock price to upset investors and employees who are counting on a biotech ceo to deliver the goods and make everyone not only rich, but also validate their decision to bet on an ambitious little company. But not every investor or employee is a winner, and that makes losers out of the ceo. But which biotech ceo is the worst? The winner this year is Jim Bianco of Cell Therapeutics (CTIC), according to a reader poll conducted by TheStreet biotech columnist, Adam Feuerstein (see his piece here). He notes that Bianco has been a long-standing nominee for the prize and finally broke through the pack by engineering a 77 percent drop in stock price, despite winning European approval for a lymphoma drug. “In many ways,” he writes, “readers are (dis)honoring Bianco for a lifetime of investor bamboozlement and self-enrichment. The numbers that define his career as ceo are stunning: total losses of more than $1.7 billion, a 99.99999999 percent drop in the value of the stock and total compensation for him and hand-picked team of executive cronies in the tens of millions of dollars.” This performance helped Bianco garner 37 percent of the record-breaking 30,239 votes cast for the annual achievement. Last year, by the way, the winner was Mitch Gold, the recently departed ceo at Dendreon (DNDN), which is struggling to make its Provenge prostate cancer vaccine a viable treatment in the face of managerial missteps and rival meds. The competition this year was fierce, though, as 31 percent of votes cast were for Jon Stonehouse of BioCryst Pharmaceuticals (BCRX), while Stephen Simes of BioSante Pharmaceuticals (BPAX) Steven King of Peregrine Pharmaceuticals (PPHM) each attracted 16 percent of the votes.
|
|
|
|
|
|
|
|
|
|
|